Nasopharyngitis

DefinitionNLM MeSH D009304

Inflammation of the NASOPHARYNX, usually including its mucosa, related lymphoid structure, and glands.

Source: U.S. National Library of Medicine — MeSH (Nasopharyngitis)

Drugs reporting Nasopharyngitis (105)

Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.

1. 1Doxecitine1100%
2. 2Doxribtimine1100%
3. 3Triclosan16833%
4. 4Leptin133%
5. 5Coal Tar22730%
6. 6Desogestrel81120%
7. 7Chlorhexidine1,54917%
8. 8Tetanus Toxin117%
9. 9Copper Gluconate114%
10. 10Elapegademase3713%
11. 11Germanium212%
12. 12Germanium Sesquioxide212%
13. 13Dibucaine1210%
14. 14Carbachol138.5%
15. 15Ciclesonide1,0217.7%
16. 16Sibeprenlimab47.0%
17. 17Dimenhydrinate7186.9%
18. 18Acitretin3076.4%
19. 19Etranacogene Dezaparvovec36.0%
20. 20Trofinetide3576.0%
21. 21Terbutaline1035.8%
22. 22Gluconate2,7395.7%
23. 23Methazolamide185.6%
24. 24Immunoglobulin G1,0885.5%
25. 25Deuruxolitinib35.5%
26. 26Retifanlimab25.4%
27. 27Ziftomenib15.3%
28. 28Acetic Acid195.1%
29. 29Paromomycin54.9%
30. 30Leniolisib364.9%
31. 31Secukinumab7,6474.8%
32. 32Tofacitinib8,8714.8%
33. 33Omalizumab3,9144.8%
34. 34Sodium Succinate2,5314.8%
35. 35Idursulfase1834.7%
36. 36Calamine204.5%
37. 37Mepolizumab2,1784.5%
38. 38Sodium Fluoride2074.4%
39. 39Ocrelizumab2,5534.2%
40. 40Palivizumab6384.2%
41. 41Folic Acid9,4823.8%
42. 42Ofatumumab1,2413.8%
43. 43Peppermint Oil403.8%
44. 44Tavaborole23.6%
45. 45Maralixibat323.6%
46. 46Olipudase Alfa43.6%
47. 47Elosulfase Alfa1883.6%
48. 48Etanercept20,7243.5%
49. 49Diphenhydramine6,7923.5%
50. 50Phenylephrine7,2193.3%
51. 51Guaifenesin6,5713.3%
52. 52Cholic Acid133.3%
53. 53Vestronidase Alfa23.2%
54. 54Prilocaine563.2%
55. 55Methotrexate15,3973.2%
56. 56Mavacamten1333.1%
57. 57Nirogacestat243.0%
58. 58Prednisone14,8683.0%
59. 59Adalimumab21,1843.0%
60. 60Vedolizumab2,4452.9%
61. 61Sparsentan1502.9%
62. 62Mitapivat212.9%
63. 63Flurandrenolide92.9%
64. 64Deflazacort1812.9%
65. 65Cysteine42.9%
66. 66Salmeterol2,9962.8%
67. 67Vamorolone392.7%
68. 68Iptacopan182.7%
69. 69Alclometasone82.6%
70. 70Laronidase1042.6%
71. 71Eliglustat392.6%
72. 72Sapropterin1582.5%
73. 73Eculizumab1,3262.5%
74. 74Natalizumab4,4752.5%
75. 75Doxylamine1892.5%
76. 76Carglumic Acid182.5%
77. 77Olezarsen102.4%
78. 78Lumacaftor2022.4%
79. 79Alirocumab5842.4%
80. 80Galsulfase862.3%
81. 81Avalglucosidase Alfa192.3%
82. 82Trientine102.2%
83. 83Ivacaftor7232.2%
84. 84Calcipotriene1422.1%
85. 85Nusinersen1602.1%
86. 86Belumosudil622.1%
87. 87Elexacaftor2512.1%
88. 88Ublituximab732.0%
89. 89Upadacitinib1,5432.0%
90. 90Tezacaftor3562.0%
91. 91Risdiplam782.0%
92. 92Dornase Alfa3802.0%
93. 93Satralizumab301.9%
94. 94Lonapegsomatropin101.8%
95. 95Ixekizumab6431.8%
96. 96Etrasimod271.7%
97. 97Risankizumab1,3081.7%
98. 98Mirikizumab121.7%
99. 99Pomalidomide1,6541.6%
100. 100Evolocumab2,5391.6%
101. 101Eteplirsen311.4%
102. 102Ritlecitinib241.4%
103. 103Deucravacitinib351.3%
104. 104Boron14—
105. 105Beta Carotene5—

Related reactions

Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.

• Influenza23 shared · 0.17
• Cough56 shared · 0.12
• Covid-1929 shared · 0.11
• Illness15 shared · 0.10
• Weight Increased26 shared · 0.09
• Product Dose Omission Issue40 shared · 0.08
• Joint Swelling12 shared · 0.08
• Inappropriate Schedule Of Product Administration16 shared · 0.07
• Psoriasis10 shared · 0.07
• Sinusitis10 shared · 0.07

Literature

Recent PubMed references pinned to Nasopharyngitis as a MeSH major topic. About the reaction term itself — not about any specific drug.

• [Herbal medicine Sinupret extract in the treatment of acute rhinitis (nasopharyngitis) in senior school-age children (adolescents)].
  Vestnik otorinolaringologii · 2025 · Shabaldina EV, Abramova NA, Shabaldin AV, et al.
  PMID 40099334DOI 10.17116/otorino20259001143
• Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
  Frontiers in immunology · 2024 · He Q, Xie X, Chen Q, et al.
  PMID 38464512DOI 10.3389/fimmu.2024.1342810
• Identifying causal relationships between gastroesophageal reflux and extraesophageal diseases: A Mendelian randomization study.
  Medicine · 2024 · Yao P, Liao X, Huang J, et al.
  PMID 38363933DOI 10.1097/MD.0000000000037054
• Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
  Frontiers in immunology · 2023 · Wu S, Xu Y, Yang L, et al.
  PMID 38106423DOI 10.3389/fimmu.2023.1294416
• Application of narrow band imaging and Lugol's iodine staining in screening for nasopharyngeal carcinoma.
  World journal of surgical oncology · 2023 · Yang F, Huang N, Chen X, et al.
  PMID 38037075DOI 10.1186/s12957-023-03258-5
• Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
  Frontiers in endocrinology · 2023 · Chen L, Xue Q, Yan C, et al.
  PMID 38027214DOI 10.3389/fendo.2023.1256548